Navigation Links
NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
Date:4/22/2010

NEW YORK and SCOTTSDALE, Ariz., April 22 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. ("NeoStem") (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China and ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBS), announced today that they have entered into a Collaborative Research Agreement, focused on the development of an advanced, adult human stem cell product. Under the agreement, NeoStem will investigate the effects of Homspera(R), ImmuneRegen's lead drug candidate, which has been shown to enhance stem cell activity, in combination with NeoStem's VSEL(TM) technology. Very small embryonic-like stem cells are a population of stem cells found in the bone marrow that can be mobilized and subsequently harvested from the peripheral blood of adults.

NeoStem is the first company to provide adult stem cell collection and banking services to the general adult population, and is pursuing the research and development of adult stem cell therapies, including therapies through the use of very small embryonic-like stem cells, for regenerative purposes, both in the U.S. and China, for a number of health conditions.

ImmuneRegen has previously reported on the effects of Homspera on the differentiation of human adult stem cells, particularly into hematopoietic stem cells that are capable of becoming blood cells and are the foundation of the body's immune system. Very small embryonic-like stem cells are also found in adults but may have broader applications and are
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. NeoStem, Inc. Awarded NIH Research and Research Infrastructure Grand Opportunities Grant
2. NeoStem, Inc. is Certified by the State of New York as a Qualified Emerging Technology Company and Notifies Investors of Possible Tax Credit of up to 20%
3. NeoStem, Inc. Appoints Leading Chinese Medical Official to Its Advisory Board
4. NeoStem, Inc. Appoints Financial Expert with Broad International Experience to the Board of Directors and to Serve as Chairman of the Companys Audit Committee
5. NeoStem, Inc. Announces Agreement With Progenitor Cell Therapy, LLC
6. NeoStem, Inc. to Enter the Regenerative Medicine Market in Asia
7. Suzanne Somers, Renowned Author, Medical Advocate, and Official Spokesperson for NeoStem, Inc., Inspires the Audience on The Ellen Degeneres Show
8. Suzanne Somers To Promote Growing Importance of Storing Your Own Adult Stem Cells Under Alliance With NeoStem, Inc.
9. ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
10. WaferGen Biosystems, ImmuneRegen BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research
11. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... An article posted earlier this week by Fox News ... probiotics. The article stated that while many products are claiming ... listed, the actual use for probiotics may go beyond ... the total uses of probiotics have not yet been discovered, ... “miracle” bacterium, and debunked the myths surrounding them. , ...
(Date:6/19/2013)... June 19, 2013 ... announced the addition of the "Global ... report to their offering. ... of data protection and old security practises ... have driven the growth of biometric technologies ...
(Date:6/19/2013)... ROCKVILLE, Md. , June 19, 2013 Synthetic ... on the prevention and treatment of serious infectious diseases, announced ... the 6 th Annual OneMedForum New York Conference on ... New York City . Mr. Riley is scheduled ... live webcast of Synthetic Biologics, presentation can be accessed by ...
(Date:6/19/2013)... Calif. , June 19, 2013  Continuing its ... myocardial infarction (MI), Beckman Coulter , Inc. announces ... of its new Access AccuTnI+3 troponin I assay for ... "Clinicians have depended on Beckman Coulter,s ... new AccuTnI+3 assay has the proven performance to continue ...
Breaking Biology Technology:Natural Acne Remedy, Probiotic Action Explains the Science behind Using Probiotics for Better Health 2Global Biometric Systems Market Forecast Report - Opportunities to 2018 2Global Biometric Systems Market Forecast Report - Opportunities to 2018 3Synthetic Biologics to Present at OneMedForum New York 2013 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 3
... , CINCINNATI, Sept. 18 LCA-Vision Inc. (Nasdaq: ... correction services under the Lasik Plus (R) brand, announces that ... a member of the company,s board of directors effective September ... ophthalmology industry. Management of daily operations will be the ...
... N.J., Sept. 17 Regado Biosciences, a privately held company ... announced today that the European Patent Office (EPO) has notified ... claims directed to oligonucleotide modulators of blood coagulation factor aptamers ... Company,s portfolio extends the scope and breadth of Regado,s intellectual ...
... , , , , ... The US Food and Drug Administration (FDA) has approved Valturna(R) ... two key points within the renin system, also known as the ... This is the first approval for Valturna, which is indicated for ...
Cached Biology Technology:LCA-Vision Announces CEO Resignation 2Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers 2Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers 3Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 2Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 3Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 4Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 5Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 6Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 7
(Date:6/19/2013)... DETROIT Insulin is the most potent physiological ... the storage and synthesis of lipids, protein and ... the circulatory system. It also plays a major ... where the glucose is metabolized and removed from ... understanding the precise molecular mechanisms by which insulin ...
(Date:6/19/2013)... 2013  New York College of Health Professions announces ... and Trademark Office for detecting biometric changes through smart ... have been injured, attacked or killed. This ... Intellectual Properties Agreements of New York College of Health ... New York College says, "Our ...
(Date:6/19/2013)... European Medicines Agency (EMA) approved the modified adeno-associated ... therapy for clinical use in the Western world. ... S447X for the treatment of a rare inherited ... affects approximately one or two out of one ... of the pancreas. Afflicted individuals carry a defect ...
Breaking Biology News(10 mins):Breakthrough research of essential molecule reveals important targets in diabetes and obesity 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 3New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 4No danger of cancer through gene therapy virus 2
... Common colds typically cause a week of sneezing, aches and ... and a few used sick days behind. But what if ... adenovirus type-3 is known as the "uncommon cold" because the ... to those of the common cold which is caused by ...
... of Census of Marine Life explorations as scientists uncover ... the global ocean. A world of marine discoveries including ... star, and Antarctica,s biggest-ever amphipod and other interesting, rare, ... http://earth.google.com/ocean . Or one can follow along on scientific ...
... been born 200 years ago come Feb. 12, but his ... And while the Origin of Species author might not have ... that the environment is changing. He would, however, be astonished ... "Every species is under temporary permanence," says Bill Saidel, ...
Cached Biology News:New vaccine developed for preventing 'uncommon cold' virus 2Evolution and climate change research advances at Rutgers-Camden 2
... the smallest thermal cyclers on the market, which ... 0.5ml (20 samples) or 0.2ml microtube (25 samples) ... and cooling rate of 3.6C/sec and 2.0C/sec respectively ... Fast track programming with new quick dial facility ...
... HRP Conjugate Stabilizer is an aqueous solution ... other non-toxic stabilizing chemicals in a MOPS ... 6.7. This product contains a combination ... ppm Proclin 300 (Rohm and Haas Company) ...
Preparation Note: Prepared by method of Wimmer, E., et al., Biochemistry, 7, 2623 (1968). Quality Clarifier: Acceptor Activity: approx. 1000 picomoles phenylalanine per A 260 unit (not determined b...
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
Biology Products: